Annual Report 2018/19

To our shareholders

Letter to shareholders

Sonova continued to deliver on its strategy in 2018/19. Highlights included the launch of a leading-edge new technology platform, delivering the highest level of hearing performance; an emphasis on operational excellence in audiological care; and good progress in cochlear implants.

Sales

2763

CHF million

+4.4% over prior year

Group sales were CHF 2,763.2 million, an increase of 4.4% in Swiss francs and of 4.1% in local currencies. Organic growth stood at 4.9% in local currencies.

EBITA

594

CHF million

+7.7% over prior year

The adjusted Group EBITA reached CHF 594.0 million, up 7.7% in Swiss francs and 6.7% in local currencies. As reported, Group EBITA reached CHF 582.5 million, up 9.4% over the prior year in Swiss Francs.

Key figures

Sales
in CHF m

Sales by regions
in 2018/19 in %

Adjusted EBITA
in CHF m

Adjusted EPS
in CHF

Operating Free Cash Flow
in CHF m

Number of
employees

Feature Story

Pioneering innovation

Sonova has been operating successfully in France for decades. We took a trip to a country where creativity and innovation lie at the heart of French “genius”.